Dawn of auditory restoration: meta-review of genetic therapy advances for congenital hearing loss

Tanvir Hussain; Olivia Norrette Breen; Sarrwar Attique; Pavol Prazenica; Alaa Almanassra

doi:10.18203/2349-3259.ijct20252706

Authors

Tanvir Hussain Department of Otolaryngology, Head and Neck Surgery, Limerick University Hospital, Ireland
Olivia Norrette Breen Audiology Department, Limerick Universty Hospital, Ireland
Sarrwar Attique Department of Otolaryngology, Head and Neck Surgery, Limerick University Hospital, Ireland
Pavol Prazenica Department of Otolaryngology, Head and Neck Surgery, Limerick University Hospital, Ireland
Alaa Almanassra Department of Otolaryngology, Head and Neck Surgery, Limerick University Hospital, Ireland

DOI:

https://doi.org/10.18203/2349-3259.ijct20252706

Keywords:

Genetic hearing loss, Gene therapy, Adeno-associated virus, Otoferlin, Cochlear gene delivery, CRISPR-Cas9, Auditory restoration, Sensorineural deafness, Clinical translation, Inner ear

Abstract

Congenital hearing loss (CHL), affecting 1-3 per 1000 newborns globally, represents a paradigm shift in therapeutic development with the advent of genetic interventions. This meta-review synthesizes evidence from 42 clinical and preclinical studies (2020-2025) demonstrating that adeno-associated virus (AAV)-mediated gene therapy has successfully restored auditory function in patients with autosomal recessive deafness 9 (DFNB9), with mean auditory brainstem response (ABR) thresholds improving from 106±9 dB to 52±30 dB within one-month post-intervention. Younger patients (5-8 years) exhibited near-complete recovery, while adults showed clinically significant improvements. The emergence of novel delivery vectors (including engineered AAVs and lipid nanoparticles), CRISPR-based editing strategies, and innovative cellular entry pathways (AAVR2 receptor) has expanded the therapeutic landscape. Despite challenges in vector tropism, immune responses, and accessibility, genetic therapies are poised to transform CHL management from amplification to biological restoration. Future research must prioritize solutions for dominant genetic forms, optimal intervention timing, and cortical reintegration pathways.

Metrics

Metrics Loading ...

References

Guthrie OW. Gene therapy: An Historical Overview for Familial Hearing loss. Int J Mol Sci. 2025;26(4):1469. DOI: https://doi.org/10.3390/ijms26041469

Cheng X, Zhong J, Zhang J, Cui C, Jiang L, Liu YW, et al. Gene Therapy vs Cochlear Implantation in Restoring Hearing Function and Speech Perception for Individuals with Congenital Deafness. JAMA Neurol. 2025. DOI: https://doi.org/10.1001/jamaneurol.2025.2053

Leclère JC, Marianowski R, Montier T. Gene therapy for Hearing loss: Current status and Future Prospects of Non-Viral Vector Delivery Systems. Hearing Res. 2024;453:109130. DOI: https://doi.org/10.1016/j.heares.2024.109130

Ivanchenko MV, Hathaway DM, Klein AJ, Pan B, Strelkova O, De-La-Torre P, et al. Mini-PCDH15 gene therapy rescues hearing in a mouse model of Usher syndrome type 1F. Nature Communicat. 2023;14(1):2400. DOI: https://doi.org/10.1038/s41467-023-38038-y

Qi J, Zhang L, Lu L, Tan F, Cheng C, Lu Y, et al. AAV gene therapy for autosomal recessive deafness 9: a single-arm trial. Nature Med. 2025. DOI: https://doi.org/10.1038/s41591-025-03773-w

Wang H, Chen Y, Lv J, Cheng X, Cao Q, Wang D, et al. Bilateral gene therapy in children with autosomal recessive deafness 9: single-arm trial results. Nature Med. 2024;30(7):1898-904. DOI: https://doi.org/10.1038/s41591-024-03023-5

Lv J, Wang H, Cheng X, Chen Y, Wang D, Zhang L, et al. AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial. The Lancet. 2024;403(10441):2317-25. DOI: https://doi.org/10.1016/S0140-6736(23)02874-X

Felder AK, Tjalsma SJD, Verhagen HJMP, Majied R, Verstegen MJAM, Verheul TCJ, et al. Reactivation of developmentally silenced globin genes through forced linear recruitment of remote enhancers. Blood. 2025;146(6):732-44. DOI: https://doi.org/10.1182/blood.2024028128

Zhang L, Dong D, Yin Y, Tang H, Lv J, Cao Q, et al. Audiological characteristics following gene therapy in patients with autosomal recessive deafness 9. Med. 2025;8(6):100696. DOI: https://doi.org/10.1016/j.medj.2025.100696

Gadenstaetter AJ, Krumpoeck PE, Landegger LD. Inner Ear Gene Therapy: An Overview from Bench to Bedside. Mol Diagnosis Therapy. 2024;29(2):161-81. DOI: https://doi.org/10.1007/s40291-024-00759-1

Zhang L, Tan F, Qi J, Lu Y, Wang X, Yang X, et al. AAV‐mediated Gene therapy for Hereditary Deafness: Progress and Perspectives. Advanced Sci. 2024;11(47):e2402166. DOI: https://doi.org/10.1002/advs.202402166

Duhon BH, Bielefeld EC, Ren Y, Naidoo J. Gene therapy advancements for the treatment of acquired and hereditary hearing loss. Front Audiol Otol. 2024;2:1423853. DOI: https://doi.org/10.3389/fauot.2024.1423853

Benamer N, Ribeuz HL, Felgerolle C, Calvet C, Postal O, Plion B, et al. Cochlear gene therapy restores hearing and auditory processing in an atypical DFNB9 mouse model. Commun Med. 2025;5(1):229. DOI: https://doi.org/10.1038/s43856-025-00926-3

Brotto D, Greggio M, De Filippis C, Trevisi P. Autosomal Recessive Non-Syndromic Deafness: Is AAV gene therapy a real chance? Audiol Res. 2024;14(2):239-53. DOI: https://doi.org/10.3390/audiolres14020022

Li L, Shen T, Liu S, Qi J, Zhao Y. Advancements and future prospects of adeno-associated virus-mediated gene therapy for sensorineural hearing loss. Front Neurosci. 2024;18:1272786. DOI: https://doi.org/10.3389/fnins.2024.1272786

Lahlou G, Calvet C, Giorgi M, Lecomte MJ, Safieddine S. Towards the clinical application of gene therapy for genetic inner ear diseases. J Clin Med. 2023;12(3):1046. DOI: https://doi.org/10.3390/jcm12031046

Hahn R, Avraham KB. Gene therapy for inherited hearing loss: updates and remaining challenges. Audiol Res. 2023;13(6):952-66. DOI: https://doi.org/10.3390/audiolres13060083

Jiang L, Wang D, He Y, Shu Y. Advances in gene therapy hold promise for treating hereditary hearing loss. Molecular Therapy. 2023;31(4):934-50. DOI: https://doi.org/10.1016/j.ymthe.2023.02.001

Tavazzani E, Spaiardi P, Contini D, Sancini G, Russo G, Masetto S. Precision medicine: a new era for inner ear diseases. Front Pharmacol. 2024;15:1328460. DOI: https://doi.org/10.3389/fphar.2024.1328460

Iranfar S, Cornille M, Roldan MS, Plion B, Lecomte MJ, Safieddine S, et al. Cell tropism of adeno-associated viruses within the mouse inner ear in vivo: from embryonic to adult stages. Sci Rep. 2025;15(1):13479. DOI: https://doi.org/10.1038/s41598-025-98007-x

Hastings ML, Brigande JV. Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction. Hearing Res. 2020;394:107931. DOI: https://doi.org/10.1016/j.heares.2020.107931

Wu X, Zhang L, Li Y, Zhang W, Wang J, Cai C, et al. Gene therapy via canalostomy approach preserves auditory and vestibular functions in a mouse model of Jervell and Lange-Nielsen syndrome type 2. Nat Commun. 2021;12(1):697. DOI: https://doi.org/10.1038/s41467-020-20808-7